From: kristoff@NET.BIO.NET (Dave Kristofferson)
Newsgroups: bionet.sci-resources
Subject: NIH Guide, vol. 21, no. 36, pt. 2, 9 October 1992
Date: 8 Oct 92 23:55:34 GMT
Distribution: bionet


$$XID NIHGUIDE 19921009 V21N36 P2O2 ************************************
unusual merit, need and promise, and in accordance with PHS policy
governing such awards.  Foreign institutions are not eligible for
First Independent Research Support and Transition (FIRST) Awards
(R29).

MECHANISM OF SUPPORT

This RFA solicits applications for the National Institutes of Health
(NIH) individual research grant (R01) and FIRST (R29) awards and is a
one-time solicitation.  Applicants, who will plan and execute their
own research programs, are requested to furnish their own estimates
of the time required to achieve the objectives of the proposed
research project.  Up to five years of support may be requested.  At
the end of the official award period, renewal applications may be
submitted for peer review and competition for support through the
regular grant program of the NHLBI.  It is anticipated that support
for the present program will begin in September 1993. Administrative
adjustments in project period and/or amount of support may be
required at the time of the award.  All current policies and
requirements that govern the research grant programs of the NIH will
apply to grants awarded in connection with this RFA.

FUNDS AVAILABLE

Although the financial plans for fiscal year 1993 include $1.5
million for this program, award of grants pursuant to this RFA is
contingent upon receipt of funds for this purpose.  It is anticipated
that about six grants will be awarded under this program.  The
specific amount to be funded will, however, depend on the merit and
scope of the applications received and on the availability of funds.
Since a variety of approaches would represent valid responses to this
announcement, it is anticipated that there will be a range of costs
among individual grants awarded.  If collaborative arrangements
involve sub-contracts with other institutions, the NHLBI Grants
Operations Branch (telephone 301-496-7257) may be consulted regarding
procedures to be followed.

RESEARCH OBJECTIVES

The following are only examples and prospective applicants are urged
to use their own ideas as to the area of research.

Development of Cell Lines and Culture Systems

The critical molecular events that lead to commitment of progenitor
cells to the megakaryocytic lineage and to complete maturation of
megakaryocytes to platelet production have not been identified.
These studies require the development of cell lines that can enter
and complete the normal maturation cycle.  Immortalized cell lines
could be generated that can be triggered to undergo differentiation
under restricted conditions.  Another approach would be to develop
bone marrow culture systems that allow the transition of stem cells
to megakaryocytes to be specifically monitored.  This approach could
employ precursor cells isolated from transgenic mice that possess
megakaryocyte-specific promotors coupled to reporter molecules in
conjunction with purified hematopoietic growth factors.  The role of
known oncogenes, growth factor receptors, and other signaling
proteins could be investigated in the above systems with dominant
negative suppressor techniques, antisense approaches, or injection of
specific neutralizing antibodies.  The function of previously
unidentified components might be sought by somatic cell genetic
techniques coupled to expression cloning methods.

Nuclear and Cytoplasmic Development

The biochemical steps that are responsible for the development and
extent of polyploidy and for maturation of the cytoplasm and the
formation of granule and membrane systems are not defined.  The
molecules that are specific to megakaryocytes and to different stages
of development must be defined; new markers other than those
currently used in studies of platelets should be sought.  The cis
acting regions and transacting factors of genes specifically
expressed in megakaryocytes should be determined, and the effects of
hematopoietic growth factors and cytokines on these events should be
assessed.

Specific areas of study that might elucidate nuclear development
include the role of cyclins, kinases, phosphatases, and contractile
proteins in endomitosis.  Specific areas of study regarding
cytoplasmic development include stage-specific events in granule
formation and synthesis of membrane and cytoskeletal components,
including targeting of proteins to specific structures.  The
mechanism by which the cytoplasm becomes organized into the mature
platelets is unknown, and studies that could address this question
would be useful.  It would also be important to identify the specific
growth factors that control nuclear and cytoplasmic development and
platelet formation.

Sensors and Signals

Investigations are needed to clarify the sensors and molecular
signals that modulate the plasma levels of the megakaryocyte specific
growth factors and thereby regulate megakaryocytopoiesis.

Platelet Production

Newly available techniques might be used to clarify questions related
to platelet production.  For example, megakaryocytes that have been
genetically labeled with short-lived reporter molecules might serve
as in vivo markers for quantitating platelet production.  The site of
megakaryocyte fragmentation might be determined by injecting the
labeled cells and measuring the formation of the circulating
platelets.

Genetic Defects in Megakaryocytopoiesis

Chromosomal abnormalities have been associated with megakaryocytic
leukemias, notably in Down syndrome and in adult leukemias in
otherwise genetically normal individuals.  Other congenital syndromes
that include defects in megakaryocytopoiesis have been identified,
such as TAR syndrome and Epstein's syndrome.  In addition, a number
of animal models of defective megakaryocytopoiesis have been
described.  Characterization of the genetic abnormalities in these
various conditions could provide useful information on the factors
regulating megakaryocytopoiesis.

Special Requirements

The NHLBI will sponsor annual meetings to encourage the exchange of
information among investigators who participate in this program.  In
the preparation of the budget for the grant application, applicants
must request additional travel funds for one meeting each year to be
held in Bethesda, MD.  Applicants must also include a statement in
the applications indicating their willingness to participate in such
meetings.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN
CLINICAL RESEARCH STUDIES

For projects involving clinical research, the NIH requires applicants
to give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.

LETTER OF INTENT

The NHLBI requests that prospective applicants submit a letter of
intent that includes a descriptive title of the proposed research and
identification of other participating institutions.  Such letters are
requested only for the purpose of providing an indication of the
number and scope of applications to be received; therefore their
receipt is not acknowledged.  A letter of intent is not binding, will
not enter into the review of any application subsequently submitted,
nor is it a necessary requirement for application.  This letter of
intent, which must be received by January 15, 1993, is to be sent to:

Dr. Charles L. Turbyfill
Division of Extramural Affairs,
National Heart, Lung, and Blood Institute
Westwood Building, Room 553
Bethesda, MD  20892

APPLICATION PROCEDURES

Applications are to be submitted on the research grant application
form PHS 398 (rev. 9/91).  This form is available from most applicant
institution's office of sponsored research or business office and
from the Office of Grants Inquiries, Division of Research Grants,
National Institutes of Health, 5333 Westbard Ave, Room 449, Bethesda,
MD  20892.  FIRST Award applications must include at least three
sealed letters of reference attached to the face page of the original
application.  FIRST Award applications submitted without the required
number of reference letters will be considered incomplete and will be
returned without review.

Application Receipt Date:  March 15, 1993

REVIEW CONSIDERATIONS

Upon receipt, applications will be reviewed for completeness by the
DRG and for responsiveness to the objectives of the RFA by the NHLBI.
Incomplete applications will be returned to the applicant without
further consideration.  If the application is not responsive to the
RFA, NHLBI staff will contact the applicant to determine whether to
return the application to the applicant or submit it for review in
competition with unsolicited applications at the next review cycle.

Applications judged to be responsive will be reviewed for scientific
and technical merit by an initial review group that will be convened
by the Division of Extramural Affairs, NHLBI, solely to review these
applications.

This initial review will include a preliminary evaluation to
determine scientific merit relative to the other applications
received in response to the RFA (triage); the NHLBI will withdraw
from further consideration applications judged to be noncompetitive
and notify the Principal Investigator/program director and the
applicant organization.  Those applications judged to be competitive
will be further evaluated for scientific/technical merit by the usual
peer review procedures.

The second level review will be by the National Heart, Lung, and
Blood Advisory Council.

INQUIRIES

Inquiries regarding this program and requests for the RFA document
to:

Dr. Pankaj Ganguly
Chief, Thrombosis and Hemostasis Branch
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Federal Building, Room 5C14
Bethesda, MD  20892
Telephone:  (301) 402-2237
FAX:  (301) 496-9940

Fiscal and administrative matters to:

Ms. Jane R. Davis
Chief, Blood Division Grants Management Section
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 4A15
Bethesda, MD  20892
Telephone:  (301) 496-7257
FAX:  (301) 402-1200

AUTHORITY AND REGULATIONS

The programs of the Division of Blood Diseases and Resources, NHLBI,
are described in the Catalog of Federal Domestic Assistance No.
93.839.  Awards will be made under the authority of the Public Health
Service Act, Section 301 (42 USC 241) and administered under PHS
grants policies and Federal Regulations, most specifically 42 CFR
Part 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or to
Health Systems Agency review.

$$R8 END ************************************************************

                     ONGOING PROGRAM ANNOUNCEMENTS

$$P1 BEGIN PA-93-004 ************************************************

SELECTIVE COGNITIVE DEFICITS IN NEURODEVELOPMENTAL DISORDERS

NIH GUIDE, Volume 21, Number 36, October 9, 1992

PA:  PA-93-004

P.T. 34; K.W. 0414005, 0715138, 1002030

National Institute of Neurological Disorders and Stroke

PURPOSE

The National Institute of Neurological Disorders and Stroke (NINDS)
encourages the submission of research grant applications to pursue a
promising new approach to cognitive neuroscience that will identify
relations between cognitive function and neurostructure through the
study of specific, atypical patterns of cognitive deficit associated
with neurodevelopmental syndromes of known or suspected biological
origin.  Examples of three clinical entities that can be studied from
this perspective are Williams syndrome, Turner syndrome and autism.
An FY 91 NINDS workshop was devoted to the discussion and
confirmation of the usefulness of in depth, systematic investigation
of patterns or profiles of selective cognitive impairment in these
unusual conditions.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention goals of "Healthy People 2000," a
PHS-led national activity for setting priorities.  This Program
Announcement, Selective Cognitive Deficits in Neurodevelopmental
Disorders, is related to the priority areas of infant health, chronic
disabling conditions, and the related area of the neurological basis
of cognition.  Potential applicants may obtain a copy of "Healthy
People 2000" (Full Report:  No. 017-001-474-0, or Summary Report:
Stock No. 017-001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, DC 20402-9325 (telephone
202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by foreign and domestic, for-profit
organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State and local governments, and
eligible agencies of the Federal Government.  Foreign institutions
are not eligible for First Independent Research Support and
Transition (FIRST) Awards (R29), program project grants (P01), and
center grants (P50).  Applications from minority individuals and
women are encouraged.

MECHANISMS OF SUPPORT

The support mechanisms for grants in this area will be the
traditional investigator-initiated research project grant (R01), the
FIRST award (R29), the program project grant (P01), and the center
grant (P50). As consistent with the aforementioned mechanisms, the
Principal Investigator or program director, as well as any
participating investigators, will plan, direct, and perform the
research.  Applicants for program project grants should contact the
NINDS representative listed below as early as possible in the
planning stages.

RESEARCH OBJECTIVES

Most of the knowledge about the neurological bases of cognitive
function in humans has been learned from studies of central nervous
system trauma or disease in adults.  Certain experiments of nature
seen in neurodevelopmental syndromes affect the central nervous
system in unique ways by producing specific as opposed to generalized
cognitive deficit.  Studies of these disorders, utilizing
neurobiological and behavioral techniques, can be expected to yield
new insights into the localization of cognitive function and the
developmental course of the syndromic cognitive profiles.

An example of this approach is an ongoing study of the biological
basis of language and other cognitive functions in which behavioral,
neuroanatomic, and neurophysiologic studies are being carried out in
patients with Williams syndrome, a rare metabolic disorder.  Children
with this sporadically occurring condition have distinctive facial
characteristics, low birth weight, digestive disorders in infancy,
mental retardation, mild microcephaly, apparent sensitive hearing and
supravalvular aortic stenosis.  A unique behavioral profile has been
identified in these patients in which there is a striking
fractionation of higher cortical functions with linguistic abilities
selectively preserved in the face of severe cognitive deficits.
Studies of the development of language in Williams syndrome children
are being conducted in conjunction with studies of brain structure
and function to address specific questions about the neural substrate
for this unusual neuropsychological profile.  This research, and
similar investigations, will contribute to our understanding of brain
organization for language, and other cognitive functions, using a
specific neurodevelopmental disorder as a model.  Such an approach
provides an unusual opportunity to investigate central issues of
developmental cognitive neuroscience.

In a parallel and possibly related investigation of autism, a
developmental disorder characterized by a profound deficiency in
social knowledge, affect, and communication, a new finding
demonstrates severe impairment in ability to shift attention, a
necessary developmental precursor to social communication.  Evidence
is presented that relates this deficit to neuroanatomic abnormalities
found in the cerebellum of autistic patients in both autopsy and
magnetic resonance imaging (MRI) studies and  to findings of damage
to the parietal lobe of the cerebrum as well.  There is a clear
contrast between autism and Williams syndrome in both behavioral
deficits and neuroanatomic findings.  Most autistic children have
aberrant language development and marked deficits in social
communication and patients with Williams syndrome have spared
linguistic abilities, but general cognitive impairment, and show an
intensity of affect, especially in social interaction.  The basis for
these behavioral distinctions may be the differences in neocerebellar
structures for which the autistic and Williams syndrome subjects show
divergent morphology.

Turner syndrome is a genetic disorder associated with monosomy X that
is characterized by a variety of somatic and cognitive deficiencies.
The classical features of the syndrome include short stature, webbed
neck, a broad chest, cubitus valgus, and failure of gonadal
development.  While females with Turner syndrome typically have
normal verbal IQ scores, they consistently show selective impairments
in tasks that are included in tests of performance IQ.  The results
of most studies present clear impairment in performance in spatial
rotation and left-right discrimination tasks.  Other studies report
deficits in visual-spatial memory, visual-motor coordination, and
motor learning.  Slower motor responses have also been demonstrated
in females with Turner syndrome.  The etiology of these cognitive
deficits is still unknown and there is considerable inter-individual
variation in the neurocognitive phenotype of Turner syndrome.
However, right hemisphere involvement is certainly indicated.
Current studies are addressing the problems of variations in patterns
of cognitive abilities with variations in karyotype in Turner
syndrome, changes in patterns of cognitive abilities in response to
hormone therapies, sources of deficits in social cognition, and
neurophysiological indications (event-related potentials) of altered
brain development in Turner syndrome.

More extensive investigations of the etiologies and effects of these
syndromes and carefully designed studies of other syndromes and
conditions that result in atypical patterns of cognitive deficit are
encouraged.  Examples are various types of hydrocephaly and the
fragile X syndrome.  Because of the multi-leveled
approach--behavioral, neurophysiological, and neuroanatomic--and the
likelihood of small samples,  multidisciplinary and collaborative
studies will be most appropriate.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH policy is that applicants for NIH clinical research grants and
cooperative agreements will be required to include minorities and
women in study populations so that research findings can be of
benefit to all persons at risk of the disease, disorder or condition
under study; special emphasis must be placed on the need for
inclusion of minorities and women in studies of diseases, disorders
and conditions which disproportionately affect them.  This policy is
intended to apply to males and females of all ages.  If women or
minorities are excluded or inadequately represented in clinical
research, particularly in proposed population-based studies, a clear
compelling rationale must be provided.

The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research
design  and sample size appropriate for the scientific objectives of
the study.  This information must be included in the form PHS 398 in
Section 1-4 of the research plan AND summarized in Section 5, Human
Subjects.  Applicants/offerors are urged to assess carefully the
feasibility of including the broadest possible representation of
minority groups.  However, NIH recognizes that it may not be feasible
or appropriate in all research projects to include representation of
the full array of United States racial/ethnic minority populations
(i.e., Native Americans (including American Indians or Alaskan
Natives), Asian/Pacific Islanders, Blacks, Hispanics).  The rationale
for studies on single minority population groups must be provided.

For the purpose of this policy, clinical research is defined as human
biomedical and behavioral studies of etiology, epidemiology,
prevention (and preventive strategies), diagnosis, or treatment of
diseases, disorders or conditions, including but not limited to
clinical trials.

The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.  For
foreign awards, the policy on inclusion of women applies fully; since
the definition of minority differs in other countries, the applicant
must discuss the relevance of research involving foreign population
groups to the United States' populations, including minorities.

If the required information is not contained within the application,
the review will be deferred until the information is provided.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed and the justification for the
selected study population is inadequate, it will be considered a
scientific weakness or deficiency in the study design and will be
reflected in assigning the priority score to the application.

All applications for clinical research submitted to NIH are required
to address these policies.  NIH funding components will not award
grants or cooperative agreements that do not comply with these
policies.

APPLICATION PROCEDURES

Applications are to be submitted on the grant application form PHS
398 (rev. 9/91) according to instructions contained in the
application kit.  Application kits are available from most
institutional offices of sponsored research and may be obtained from
the Office of Grants Inquiries, Division of Research Grants, National
Institutes of Health, Westwood Building, Room 449, Bethesda, MD
20892, telephone 301-496-7441.

Check "yes" in item 2a on the face sheet of the application and type
"Selective Cognitive Deficits in Neurodevelopmental Disorders."
FIRST Award applications must include at least three sealed letters
of reference attached to the face page of the original application.
FIRST Award applications submitted without the required number of
reference letters will be considered incomplete and will be returned
without review.  Applicants for the P01 or P50 must use the
application format described in the NINDS pamphlet, NINDS GUIDELINES:
PROGRAM PROJECT AND RESEARCH CENTER GRANTS (Revised June 1992).
Deadlines for the receipt of applications are February 1, June 1, and
October 1.  The completed original application and five exact copies
must be sent or delivered to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

If the application is for a program project or center grant, please
send the original and three copies to the Division of Research
Grants.  An additional two copies sent to the address below would be
useful for expediting the processing of applications for
multidisciplinary efforts.

Applications will be assigned on the basis of established Public
Health Service referral guidelines.  Applications will be judged on
scientific merit and program relevance in accordance with NIH policy
and procedures involving peer review.  An initial review will be made
by an appropriate study section of the Division of Research Grants
for research grants (R01) and FIRST awards (R29), and by an
appropriate institute committee for program projects (P01) and
centers (P50).  A second level of review will be made by an
appropriate national advisory council.

AWARD CRITERIA

Applications assigned to the NINDS will compete for available funds
with all other approved applications assigned to the NINDS.  The
following will be used in making funding decisions:

o  Quality of the proposed project as determined by peer review
o  Availability of funds
o  Program balance among research areas of the announcement

INQUIRIES

For further information regarding this announcement, potential
applicants may write or call:

Sarah H. Broman, Ph.D.
Developmental Neurology Branch
National Institute of Neurological Disorders and Stroke
Federal Building, Room 8C-06
Bethesda, MD  20892
Telephone:  (301) 496-5821

For fiscal and administrative inquiries regarding this announcement,
potential applicants may write or call:

Dwight Mowery
Grants Management Branch
National Institute of Neurological Disorders and Stroke
Federal Building, Room 1004
Bethesda, MD  20892
Telephone:  (301) 496-9231

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance Nos. 93.853 and 93.854.  Awards are made under
authorization of the Public Health Service Act, Title IV, Part A
(Public Law 78-410, as amended by Public Law 99-150, 42 USC 241 and
285) and administered under PHS grants policies and Federal
Regulations 42 CFR 52 and 45 CFR Part 74.  This program is not
subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review.

$$P1 END ************************************************************

$$P2 BEGIN PA-93-005 ************************************************

ARTHRITIS & SKIN DISEASES (MINORITY POPULATIONS)

NIH GUIDE, Volume 21, Number 36, October 9, 1992

PA NUMBER:  PA-93-005

P.T. 34, FF; K.W. 0715010, 0715185

National Institute of Arthritis and Musculoskeletal and Skin Diseases

PURPOSE

The National Institute of Arthritis and Musculoskeletal and Skin
Diseases invites investigator-initiated grant applications and
supplemental applications to carry out clinical and epidemiologic
studies on the etiology, treatment, and prevention of arthritis,
musculoskeletal, and skin diseases in minority populations and other
populations at special risk.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This program
announcement, Arthritis and Skin Diseases (Minority Populations), is
related to the priority area of chronic disabling conditions and
surveillance objectives.  Potential applicants may obtain a copy of
"Healthy People 2000" (Full Report:  Stock No. 017-001-00474-0) or
"Healthy People 2000" (Summary Report:  Stock No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Research grant applications may be submitted by domestic and foreign
for profit and non-profit organizations, public and private, such as
local governments, and eligible agencies of the Federal Government.
Applications with minority individuals and women as Principal
Investigators are encouraged.  Foreign institutions are not eligible
for First Independent Research Support and Transition (FIRST) Awards
(R29).  Applicants for the Clinical Investigator Awards (K08) and
Individual National Research Service Awards (F32) must be U.S.
citizens, non-citizen nationals, or non-citizens lawfully admitted
for permanent residence.  Applicants for the F32 Award must have
received a doctorate degree as of the beginning date of the NRSA
appointment.  Applicants for the K08 Award must have an M.D. or
equivalent degree.  Applicants for the Fogarty International Research
Collaboration Award (FIRCA) Award must be U.S. scientists who are
Principal Investigators of NIH Research Project Grants (R, P, or U01
series) that are active and funded during the proposed FIRCA grant
award period.  Recipients of K awards are not eligible.  For the
FIRCA Award, the foreign collaborator's institution must be located
in a country in the geographical regions commonly known as Central
and Eastern Europe (including the former USSR), Latin America, and
the non-US Caribbean.

MECHANISMS OF SUPPORT

Applications for the following mechanisms are considered appropriate
responses to this announcement:  the traditional research project
grant (R01) and the FIRST Award (R29), the Clinical Investigator
Award (K08), and the Individual National Research Service Award
(F32).  In addition, the FIRCA funding mechanism may be used by NIH
grantees in the U.S. to collaborate with foreign investigators.
Joint efforts between U.S. and foreign investigators are encouraged.

Because the nature and scope of the research proposed in response to
this RFA may vary, it is anticipated that the size of an award will
vary also.

SUMMARY

o  Background

Major gaps in knowledge still exist about the incidence, prevalence,
and natural history of most of the rheumatic, musculoskeletal, and
skin diseases. The skin diseases in particular have lacked
epidemiologic research.  Although both cross-sectional and
longitudinal studies are lacking for many diseases, the greatest need
is for longitudinal investigations.  Some population-based
longitudinal data sources are available for studies of rheumatic
diseases and osteoporosis, e.g., Framingham, Massachusetts;
Rochester, Minnesota; NHANES I and Followup; and the Study of
Osteoporotic Fractures (SOF).

In the past decade, epidemiologic studies have made some progress in
describing the frequency of osteoarthritis and some skin diseases,
based upon nationally collected data by the National Center for
Health Statistics.  Epidemiologic studies from defined populations
have contributed knowledge about cohorts at increased risk of
disease, e.g., rheumatoid arthritis in Pima Indians and the higher
incidence, prevalence, and mortality of systemic lupus erythematosus
in Black females than in Caucasian and male populations.  However,
the key question, why some cohorts remain at increased risk of
disease, is still unanswered.

In general, less is known about the occurrence of arthritis,
musculoskeletal, and skin diseases in American Blacks than in whites.
Even less is known about other American minority groups.  Data are
also lacking on these diseases in children and the elderly.

o  Research Objectives and Scope

The primary objective of this program announcement is to foster
epidemiologic research in minority groups and other populations at
special disease risk.  Studies to be encouraged include:

o  The descriptive pattern of arthritis, musculoskeletal and skin
diseases in populations

o  The etiology and modes of transmission of these diseases,
including the relative contribution of both genetic and environmental
factors influencing both the onset and course of the disease

o  Studies of disease burden, specifically on the frequency, cost,
and personal and social sequelae of arthritis and musculoskeletal and
skin diseases

o  New diagnostic technologies to update or develop criteria for the
diagnosis and staging of many rheumatic and skin diseases and to
define homogeneous clinical subsets for epidemiologic and basic
science studies

o  Studies to generate and test etiologic hypotheses, especially for
less studied rheumatic, musculoskeletal, and skin diseases

o  Family studies to evaluate the interplay of genetic and
environmental contributions to the development and progression of
rheumatic, musculoskeletal, and skin diseases

o  Longitudinal studies to describe the prognosis and outcomes among
patients with rheumatic, musculoskeletal, and skin diseases, and to
identify risk factors for disease onset, progression, and disability

o  Practical outcome assessment tools to define the impact of
different medical, surgical, and rehabilitation management approaches
for arthritis, musculoskeletal and skin diseases

STUDY POPULATIONS

Epidemiologic studies of the general population at risk for disease,
as well as patient populations that have been diagnosed to have the
diseases, will be accepted.  Although new research projects are
desired, applications based on on-going studies that were conceived
for reasons other than the purposes of this program announcement are
also encouraged.

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH policy is that applicants for NIH clinical research grants and
cooperative agreements are required to include minorities and women
in study populations so that research findings can be of benefit to
all persons at risk of the disease, disorder or condition under
study; special emphasis must be placed on the need for inclusion of
minorities and women in studies of diseases, disorders and conditions
which disproportionately affect them.  This policy is intended to
apply to males and females of all ages.  If women or minorities are
excluded or inadequately represented in clinical research,
particularly in proposed population-based studies, a clear compelling
rationale must be provided.

The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of
the study.  This information must be included in the form PHS 398
(rev. 9/91) in Sections 1-4 of the Research Plan AND summarized in
Section 5, Human Subjects.  Applicants are urged to assess carefully
the feasibility of including the broadest possible representation of
minority groups.  However, NIH recognizes that it may not be feasible
or appropriate in all research projects to include representation of
the full array of United States racial/ethnic minority populations
(i.e., Native Americans (including American Indians or Alaskan
Natives), Asian/Pacific Islanders, Blacks, Hispanics).  The rationale
for studies on single minority population groups must be provided.

For the purpose of this policy, clinical research is defined as human
biomedical and behavioral studies of etiology, epidemiology,
prevention (and preventive strategies), diagnosis, or treatment of
diseases, disorders or conditions, including but not limited to
clinical trials.

The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.

For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.

If the required information is not contained within the application,
the review will be deferred until the information is provided.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the
selected study population is inadequate, it will be considered a
scientific weakness or deficiency in the study design and will be
reflected in assigning the priority score to the application.

All applications for clinical research submitted to NIH are required
to address these policies.  NIH funding components will not award
grants or cooperative agreements that do not comply with these
policies.

APPLICATION PROCEDURES

Applications for the R01, R29, K08, and FIRCA awards are to be
submitted on the grant application form PHS 398 (rev. 9/91) and will
be accepted at the standard application deadlines as indicated in the
application kit.  FIRST (R29) Award applications must include at
least three sealed letters of reference attached to the face page of
the original application.  First Award applications submitted without
the required number of reference letters will be considered
incomplete and will be returned to the applicant without review.  The
receipt dates for applications for AIDS-related research are also
found in the PHS 398 (rev. 9/91) application kit.  Supplemental
application instructions for the K08 Award and the application dates
are available in the publication "The K Awards" (rev. 10/91).
Supplemental application instructions for the FIRCA award are
available from the John E. Fogarty International Center.
Applications for the FIRCA Award must include a letter of
collaboration from the foreign investigator and the foreign
investigator's biographical sketch, resources, and environment.
Applications for the F32 Award are to be submitted on form PHS 416-1
and must include letters of reference and other supplemental
material.

Application kits and information booklets including relevant receipt
dates are available at most institutional offices of sponsored
research and may be obtained from the Office of Grants Inquiries,
Division of Research Grants, National Institutes of Health, Westwood
Building, Room 449, Bethesda, MD 20892, telephone 301/496-7441.  The
title and number of the announcement must be typed in Section 2a on
the face page of the application.

The completed original application and the appropriate number of
legible copies, as specified in the application kits, must be sent or
delivered to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

REVIEW PROCEDURES

Applications will be assigned on the basis of established Public
Health Service referral guidelines.  Applications will be reviewed
for scientific and technical merit in accordance with the standard
NIH peer review procedures.  FIRCA Award applications will be
reviewed by an initial review committee convened by the Fogarty
International Center.

Following scientific-technical review, the applications will receive
a second-
level review by an appropriate advisory council.

AWARD CRITERIA

Applications will compete for available funds with all other approved
applications.  The following will be considered in making funding
decisions:

o  Quality of the proposed project as determined by peer review
o  Availability of funds
o  Program balance among research areas of the announcement

Additional criteria for R29 and F32 applications include the
potential for the applicant to carry out independent research, the
quality of education, scientific training, research experience, and
commitment to a research career, as well as the institutional
commitment.  Further criteria for F32 applications include the
quality of the sponsor and training environment and the reference
reports.

INQUIRIES

Written and telephone inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Ms. Reva C. Lawrence
Epidemiology/Data Systems Program Officer
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Building 31, Room 4C-13
Bethesda, MD  20892
Telephone:  (301) 496-0434

Direct inquiries regarding fiscal matters to:

Ms. Diane M. Watson
Grants Management Officer
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Westwood Building, Room 4A15C
Bethesda, MD  20892
Telephone:  (301) 496-7257

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance No. 93.846, Arthritis, Musculoskeletal and Skin Diseases
Research.  Awards will be made under the authority of the Public
Health Service Act, Title III, Section 301 (Public Law 410, 78th
Congress, as amended, 42 USC 241) and administered under PHS grants
policies and Federal regulations 42 CFR Part 52 and 45 CFR Part 74.
This program is not subject to intergovernmental review requirements
of Executive Order 12372 or Health Systems Agency review.

$$P2 END ************************************************************

                               ERRATUM

$$E1 BEGIN R2 19920925 APPEND RFA HL-92-11-P BOTH **********************

DIETARY PATTERNS AND BLOOD PRESSURE

NIH GUIDE, Volume 21, Number 36, October 9, 1992

RFA:  HL-92-11-P

P.T. 34; K.W. 0710095, 0715115, 0755015

National Heart, Lung, and Blood Institute

Letter of Intent Receipt Date:  December 1, 1992
Application Receipt Date:  January 15, 1993

This is to announce a change in the Letter of Intent Receipt Date and
the Application Receipt Date that published in the NIH Guide for
Grants and Contracts, Vol. 21, No. 34, September 25, 1992.

The new Letter of Intent Receipt Date is December 1, 1992 (changed
from November 1, 1992).
The new Application Receipt Date is January 15, 1993 (changed from
December 1, 1992).

$$E1 END ************************************************************


$$XID RFA HD9401 HD-94-01 P1O1 *****************************************

SPECIALIZED RESEARCH CENTER PROGRAMS OR CENTER CORE GRANTS TO SUPPORT
RESEARCH IN REPRODUCTION

NIH GUIDE, Volume 21, Number 36, October 9, 1992

RFA:  HD-94-01

P.T. 04; K.W. 0413002, 0710110, 0710115, 0710030

National Institute of Child Health and Human Development

Letter of Intent Receipt Date:  January 2, 1993
Application Receipt Date:  May 18, 1993

PURPOSE

The National Institute of Child Health and Human Development (NICHD)
provides funding for a limited number of research centers in the
reproductive sciences.  These centers are broadly based investigative
endeavors encompassing research of a biomedical nature.  They are
supported through either Center Core Grants (P30) or Specialized
Research Center Grants (P50).

These centers form a national network that fosters communication,
innovation, and high quality research. Reproductive Sciences Research
Centers provide a stimulating, multidisciplinary environment that
attracts and nurtures both established and promising young
investigators.  Each Center works closely with the NICHD staff in
participating in a Center Network and in carrying out its objectives
in a manner consistent with the goals and mission of the NICHD.

BACKGROUND

The Reproductive Sciences Branch (RSB) of the Center for Population
Research (CPR) of the NICHD supports basic and clinical research on
reproduction that relies on a variety of approaches in biomedical
sciences.  Among the grant mechanisms used to provide research
support, the RSB uses:

(1) Specialized Research Center Grants (P50s) which support
integrated groups of research projects and supporting core service
facilities.  The research activities included in such project grants
must comprise, by definition, a multidisciplinary approach to
biomedical problems in reproduction.  These research programs may
have more than one theme, focus, or emphasis but all of the projects
involved must be responsive to one or more specific research areas of
reproduction promulgated by the RSB.

(2) Center Core Grants (P30s) which support Center Core facilities
designed to enhance existing federally supported research projects
within the purview of the RSB, CPR, NICHD.  Such center awards
require a critical mass of individual awards for which coordinated
technical support would be cost-effective to the NIH.  Core Grants
provide no funds for the direct support of research projects other
than for new program development; however, by making cost-effective
resources and facilities available, they enhance the productivity of
existing projects that are either integrated in a specialized
research area or organized within a central theme of research.

At present, the RSB supports a fixed number of centers with a
commitment of five years of support that is competitively renewable
for additional five-year periods.  Committed support for one P50
Center and three P30 Centers ends in FY 1994, and it is anticipated
that these Centers will submit renewal applications.  While there are
no additional Center positions available at this time, new groups of
investigators, in addition to the current awardees, are invited to
compete for the existing four positions in FY 1994.

HEALTHY PEOPLE 2000

The Public Health Service is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas. This RFA,
Specialized Research Center Programs or Center Core Grants to Support
Research in Reproduction, is related to the area of family planning.
Potential applicants may obtain a copy of "Healthy People 2000" (Full
Report:  Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary
Report:  Stock No. 017-001-00473-1) through the Superintendent of
Documents, Government Printing Office, Washington, DC 20402-9325
(telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Domestic institutions are eligible to apply for these centers.
Applications prepared for this competition may not propose
multi-institutional consortium arrangements.  In order to receive
funding, an individual domestic institution's application for a
specialized reproductive research center (P50) must have three or
more related, integrated, and high quality research projects that
provide a multidisciplinary, yet thematic, approach to the problems
to be investigated.  These research projects may be accompanied by an
appropriate number and type of core facilities, as described below,
providing cost-effective technical support.

The concurrent submission of an R01 or R29 research project
application to do essentially the same research as that proposed in a
subproject of a P50 Center application is permissible within the
context of extant NIH policy.  As a general policy, preference in
selection for funding by NICHD will be given to the subprojects of
the P50 Center in order to maintain the integrity of the program and
the validity of its merit assessment.  The coincident R01 or R29
application(s) will usually be expected to be withdrawn or
relinquished.  P50 projects must address one or more of the announced
biomedical topics to be eligible for funding.

A domestic institution's application for a reproductive sciences
research Center Core facility (P30) must be predicated on the
existence of a comprehensive research base in the reproductive
sciences comprised of a substantial number of relevant, eligible, and
funded research grants which will be active on April 1, 1994.  Such
grant projects must directly address one or more of the announced
biomedical topics to be eligible for inclusion in the center.  A
majority of these grants must be supported by the NICHD. In addition,
the eligibility for funding a core in a P30 Center is determined by
the demonstrated need of a minimal number of three relevant NIH (or
other federally reviewed and funded) research grants from the
research base in the application.  P30 Center grant funds support
only active users of the core facilities and services from the
research base (projects) proposed in the Center grant application and
only serve programs of scientific research relevant to the mission of
the RSB, CPR.

Core facilities eligible for support under this announcement are
organized activities directly providing reagents, assays,
sophisticated technical services and technical expertise in areas
required by multiple projects of a center.  Such Core facilities
neither directly conduct project type research nor serve as a funding
source for non-Center technical services available elsewhere at the
institution.  It is expected that such Core facilities will be
organized to provide training only for eligible users and only to the
extent necessary to utilize the Core effectively.  The general
guideline request for information demonstrating research training
program history and availability pertains to discussing the overall
richness of the environment of the Center's setting and should not be
confused with Core service needs per se.

If a New Program Development (NPD) component is requested, it must be
a single investigator's project description with a research plan
formatted in the usual NIH research project style.  Sufficient detail
should be provided to allow a full peer-review evaluation of its
merits.

New Specialized Research Center Grant (P50) applications may not
request more than $600,000 in direct costs for the first year.  New
Center Core Grant (P30) applications may not request more than
$500,000 in direct costs for the first year.  Renewal applications
from existing P30 or P50 Centers may not request initial year direct
costs exceeding 120 percent of the Council recommended direct costs
for the final year of the preceding project period.  Unless prior
written approval of the NICHD has been obtained, applications with
requests exceeding these guidelines will be administratively
withdrawn by the NICHD and returned to the applicant.

MECHANISM OF SUPPORT

The support mechanisms for these programs are the P50 Specialized
Reproductive Sciences Research Center Grant and the P30 Reproductive
Sciences Research Center Core Grant.  The applications should be
prepared in a manner consistent with the policy and instructional
details of this RFA and the general guidelines presented in the
publications entitled either P50 SPECIALIZED RESEARCH CENTER GRANT
GUIDELINES or P30 CENTER CORE GRANT GUIDELINES that are available
from the NICHD offices listed below.  The current policies and
requirements that govern the research grant programs of NIH will
prevail (Code of Federal Regulations, Title 42, Part 52 and Title 45,
Part 75).  The total project period for applications submitted to
this RFA is five years.  The anticipated award date will be April 1,
1994.

FUNDS AVAILABLE

Although this solicitation is included in the fiscal plans for FY
1994, support for these center grants is contingent upon the receipt
of funds for these purposes.  The number of grants to be awarded is
also contingent upon a sufficient number of applications receiving
high enough levels of merit to be considered for an award.  It is
expected that up to four awards will be made as a result of this
announcement within the expected total costs limit of $3,600,000
available for the first year.

RESEARCH OBJECTIVES

The ultimate goals of biomedical research in the reproductive
sciences are to develop new knowledge leading to clinical
applications that will enable men and women to control their
fertility with methods that are safe, effective, inexpensive,
reversible, and acceptable to various population groups, and to
overcome problems of infertility and reproductive disorders.
Domestic U.S. Reproductive Sciences centers designated as
"Specialized Reproductive Sciences Research Centers" (P50s) and as
"Reproductive Sciences Research Centers" (P30s) are awarded funds for
the support of comprehensive reproductive research programs of high
quality that focus on topics deemed to be of high priority and
significance because of their critically important relationship to
the mission of the RSB, CPR.

This Request for Applications (RFA) is specifically designed to
stimulate the reproductive sciences research community to organize or
to maintain reproductive sciences research centers of outstanding
quality that, serving as national research resources, form a network
that fosters communication, innovation, and high quality research.
Applications are encouraged for the biomedical topics listed below:

1.  Reproductive medicine:  Fertility and infertility aspects

2.  Mechanism(s) of follicular selection, atresia and ovulation

3.  Neuroendocrinology of reproduction:  Clarification of the
regulatory mechanisms of the hypothalamo-pituitary-gonadal axis
related to fertility

4.  Regulatory mechanism(s) of gametogenesis

5.  Mechanism of action of reproductive hormones, particularly at the
cellular and genetic level; modification of action by growth factors

6.  Mechanisms regulating gonadal or genital tract functions

7.  Studies on fertilization, preimplantation embryo development, or
blastocyst implantation

8.  Immunological mechanisms regulating fertility

SPECIAL REQUIREMENTS

Applicants must request travel funds to attend an annual meeting of
the directors of P50s and P30s.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH policy is that applicants for NIH clinical research grants and
cooperative agreements will be required to include minorities and
women in study populations so that research findings can be of
benefit to all persons at risk of the disease, disorder or condition
under study; special emphasis should be placed on the need for
inclusion of minorities and women in studies of diseases, disorders
and conditions which disproportionately affect them.  This policy is
intended to apply to males and females of all ages.  If women or
minorities are excluded or inadequately represented in clinical
research, particularly in proposed population-based studies, a clear
compelling rationale should be provided.

The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of
the study.  This information should be included in the form PHS 398
(rev. 9/91) in Sections 1-4 of the Research Plan AND summarized in
Section 5, Human Subjects.  Applicants are urged to assess carefully
the feasibility of including the broadest possible representation of
minority groups.  However, NIH recognizes that it may not be feasible
or appropriate in all research projects to include representation of
the full array of United States racial/ethnic minority populations
(i.e., Native Americans (including American Indians or Alaskan
Natives), Asian/Pacific Islanders, Blacks, Hispanics).

The rationale for studies on single minority population groups should
be provided.  For the purpose of this policy, clinical research
includes human biomedical and behavioral studies of etiology,
epidemiology, prevention (and preventive strategies), diagnosis, or
treatment of diseases, disorders or conditions, including but not
limited to clinical trials.

The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded. However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.

For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States populations, including
minorities.

If the required information is not contained within the application,
the application will be returned.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the
selected study population is inadequate, it will be considered a
scientific weakness or deficiency in the study design and will be
reflected in assigning the priority score to the application.

All applications for clinical research submitted to NIH are required
to address these policies.  NIH funding components will not award
grants or cooperative agreements that do not comply with these
policies.

LETTER OF INTENT

Interested applicants should contact the RSB staff for an advisory
consultation regarding reproductive sciences center grants (P50s and
P30s).  If an applicant intends to apply, it is strongly recommended,
but not mandatory, that the applicant send a letter of intent to the
RSB staff at the address listed below by January 2, 1994.  This
letter is to include a list of the titles of relevant research
projects to be associated with the center, and the names of relevant
key investigators.  The letter of intent should be received by the
RSB no later than January 2, 1993, but applicants are encouraged to
send it as soon as they decide to apply for the grant so that the RSB
staff can be of maximum assistance in the application process.  The
letter of intent is to be sent to the RSB staff contact listed at the
end of this RFA.

APPLICATION PROCEDURES

The grant application form PHS 398 (rev. 09/91) is to be used to
prepare these applications.  The RFA number (HD-94-01) and the type
of center grant request (P50 or P30) must be indicated on the face
page of the application in item 2a.  The RFA label available in the
PHS form 398 must be affixed to the bottom of the face page.  Failure
to use this label could result in delayed processing of the
application such that it may not reach the review committee in time
for review.  The PHS 398 form is available from most business offices
or grant/contract offices at most institutions and can also be
obtained from NIH by calling 301/496-7441.

It is especially important that applicants obtain and follow the
supplemental NICHD guidelines for preparing the application.  These
guidelines address special organizational aspects that require
certain tabulations in addition to the usual instructions.
Applications must be submitted by May 18, 1993.  Send or deliver the
original, completed, signed application and three, signed complete
copies to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

In addition to those applications mailed to the Division of Research
Grants, two copies of the application must be sent under separate
cover directly to:

Laurance Johnston, Ph.D.
Division of Scientific Review
National Institute of Child Health and Human Development
Building 6100, Room 5E01
Bethesda, MD  20892

Late applications will not be accepted and will be returned to the
applicants.

REVIEW CONSIDERATIONS

An administrative review of the application will be performed by the
Review, Program, and Grants Management staff for conformance to NIH
policy and NICHD guidelines, as well as for relevance to the program
purview of the RSB.  Applications that fail to comply with NIH policy
and/or NICHD guidelines will be formally returned to the applicant.
Applications may be subjected to a triage by a peer review group to
determine their potential competitiveness relative to other
applications submitted.  The Institute will withdraw from competition
those applications judged by the triage procedure to be
noncompetitive and notify the applicants and institutional business
officials.

Those applications judged to be competitive will be further evaluated
by peer review for scientific/technical merit.  The Scientific Review
Administrator (SRA) of the Population Research Committee (PRC),
NICHD, may forward the application to selected members of the PRC for
their evaluation to determine if a site visit is needed.  A site
visit, however, is not a prerequisite for consideration of an
application by the PRC.  If a site visit is required, the SRA will
communicate with the applicant for the visit arrangements as
described in the guidelines.  The initial review for scientific merit
will be carried out by the PRC in November 1993.  The second-level
review will be made by the National Advisory Child Health and Human
Development Council in January 1994.  The earliest possible funding
date is April 1, 1994.  Review procedures and criteria are detailed
in the P50 SPECIALIZED RESEARCH CENTER GRANT GUIDELINES and P30
CENTER CORE GRANT GUIDELINES (available from the NICHD offices listed
below).

AWARD CRITERIA

The anticipated date of award is April 1, 1994.  Funding decisions
will be based on the IRG and NACHHD Council recommendations, program
relevance, and the availability of funds.

INQUIRIES

For further information regarding programmatic issues, contact:

Julia Lobotsky, M.S.
Reproductive Sciences Branch
Center for Population Research
National Institute of Child Health and Human Development
Building 6100, Room 8B01
Bethesda, MD  20892
Telephone:  (301) 496-6515

For information on budget and fiscal matters, contact:

Melinda Nelson
Office of Grants and Contracts
National Institute of Child Health and Human Development
Building 6100, Room
Bethesda, MD  20892
Telephone:  (301) 496-5481

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance No. 93.864, Population Research.  Awards will be made
under the authority of the Public Health Service Act 301 (42 USC 241)
and 441 (USC 289d) and administered under PHS grants policies and
Federal Regulations 42 CFR Part 52 and 45 CFR Part 74.  This program
is not subject to A-95 or Health Systems Agency review.